 |
|
|
|
|
|
|
|
 |
Results for 'Pharmaceutical Discovery & Development Report' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Commercial Opportunities from Biomarkers
Transforming drug discovery, clinical development and molecular diagnostic
|
May 2006 |
£1495 |
50 % |
Biomarkers
technologies,markets and companies
|
December 2008 |
£2395 |
38.5 % |
Virtual Pharma
The Radical Route To Success
|
September 2008 |
£795 |
38 % |
Bioinformatics
Technical Status and Market Prospects
|
August 2005 |
£3320 |
37.5 % |
The China Pharmaceutical Market: A Strategic Opportunity Analysis
|
January 2007 |
£600 |
35 % |
Licensing Strategies - Examining Todays Pharmaceutical Licensing Trends
|
November 2007 |
£7600 |
34.3 % |
Guide to Royalty Rates in Pharmaceutical Licensing Deals; A
2007
|
January 2007 |
£4500 |
33.6 % |
Early Stage and Discovery Deals
Strategy, Structure and Payment Terms 2nd Edition
|
January 2007 |
£1350 |
33.5 % |
India: Pharmaceutical and biotechnology opportunities
|
April 2006 |
£600 |
33 % |
Pharmaceutical Outsourcing Strategies
Market expansion, offshoring and strategic management in the CRO and CMO marketplace
|
April 2006 |
£1495 |
32 % |
Indian Medical Market Report
2005
|
May 2005 |
£760 |
32 % |
Stakeholder Opinions: Diagnostics in Neurology
Predictive Biomarkers Expand Drug Revenues
|
July 2008 |
£2005 |
31 % |
Indian Pharmaceutical Industry, The:
|
March 2005 |
£3335 |
30.8 % |
Introduction of 101 China-based CROs/CMOs serving Western Pharmaceutical and Biotechnology Industry
|
April 2008 |
£615 |
30.5 % |
Strategic Outlook on Protein Kinase Inhibitors in Oncology
|
February 2006 |
£1780 |
30 % |
Drug Delivery Markets, Vol II
Implantable Injectable
|
February 2007 |
£1705 |
30 % |
Predictive ADME and Toxicology Strategies
Challenges and opportunities for in vivo, in vitro and in silico predictive technologies
|
January 2006 |
£1495 |
29.5 % |
The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics
|
April 2008 |
£2055 |
29.5 % |
Uniting R&D and Marketing for Integrated Early-Stage Market Preparation
|
May 2007 |
£5265 |
29.5 % |
Innovations and Trends in Clinical Trials
Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
|
March 2007 |
£1540 |
29.4 % |
Novel Targets in Drug Discovery
A new era in therapy
|
April 2004 |
£595 |
29.05 % |
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology
|
December 2006 |
£3150 |
29 % |
Isis Pharmaceuticals Inc
Premium Company Profile
|
December 2007 |
£265 |
29 % |
Stakeholder Opinions
Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies
|
July 2008 |
£3800 |
28.35 % |
Nanotechnology
Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics
|
January 2008 |
£1995 |
28.35 % |
Pharmaceutical Sales Force Effectiveness Metrics
Are You Measuring the Wrong Things?
|
November 2007 |
£497 |
28 % |
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
Equipment, Technologies and Companies, 2006-2011
|
January 2007 |
£1125 |
28 % |
Neurogen Corporation
Premium Company Profile
|
January 2008 |
£265 |
28 % |
Drug Discovery Tools for High-Content Analysis
|
July 2007 |
£1370 |
27.65 % |
Pharmaceutical Product Development Inc. -Deals & Alliances Report
|
February 2008 |
£300 |
27.5 % |
Array Biopharma Inc.
Premium Company Profile
|
December 2007 |
£265 |
27 % |
Alliance Pharmaceutical Corp. -Deals & Alliances Report
|
February 2008 |
£300 |
27 % |
KV Pharmaceutical Co. -Deals & Alliances Report
|
February 2008 |
£300 |
27 % |
Teva Pharmaceutical Industries Ltd. -Deals & Alliances Report
|
February 2008 |
£300 |
27 % |
Taro Pharmaceutical Industries Ltd. -Deals & Alliances Report
|
February 2008 |
£300 |
27 % |
BioMarin Pharmaceutical Inc. -Deals & Alliances Report
|
February 2008 |
£300 |
27 % |
Evaluation of Current Service Capabilities of Chinese Pharmaceutical Outsourcing Service Industry
|
May 2008 |
£2050 |
27 % |
Personalized Medicine
scientific & commercial aspects
|
December 2008 |
£2735 |
27 % |
Par Pharmaceutical Companies Inc. -Deals & Alliances Report
|
February 2008 |
£300 |
27 % |
West Pharmaceutical Services Inc. -Deals & Alliances Report
|
February 2008 |
£300 |
27 % |
Caraco Pharmaceutical Laboratories Ltd. -Deals & Alliances Report
|
February 2008 |
£300 |
27 % |
Medicis Pharmaceutical Corp. -Deals & Alliances Report
|
February 2008 |
£300 |
27 % |
Nastech Pharmaceutical Company, Inc. -Deals & Alliances Report
|
February 2008 |
£300 |
27 % |
Nymox Pharmaceutical Corp. -Deals & Alliances Report
|
February 2008 |
£300 |
27 % |
Chugai Pharmaceutical Co. Ltd. -Deals & Alliances Report
|
February 2008 |
£300 |
27 % |
Biotech 2010
|
June 2006 |
£3320 |
26.95 % |
The Indian Pharmaceutical Market to 2011
Competitive dynamics and major players
|
July 2007 |
£1495 |
26.5 % |
Pharmaceutical Contract Manufacturing and Research
|
May 2005 |
£3320 |
26.5 % |
Nitric Oxide
Therapeutics, Markets and Companies
|
December 2008 |
£1915 |
26 % |
Biopartnering Strategies
Maximizing returns from biotechnology deal-making
|
December 2006 |
£1495 |
26 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
26 % |
Bioinformatics Markets
Strategies, Business Models and Trends for the Future
|
June 2006 |
£2325 |
25.9 % |
Infinity Pharmaceuticals Inc
Premium Company Profile
|
December 2007 |
£265 |
25.5 % |
Medical Imaging Markets, Volume IV
Contrast Agents
|
February 2007 |
£2050 |
25.5 % |
European Animal Health Regulations (2 volumes)
|
January 2007 |
£895 |
25 % |
Guide to Pharmaceutical Outsourcing in China
|
February 2008 |
£2050 |
24.5 % |
Supergen Inc
Premium Company Profile
|
December 2007 |
£265 |
24.5 % |
OSI Pharmaceuticals - SWOT Analysis
|
November 2007 |
£66 |
24.5 % |
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
|
August 2006 |
£3150 |
24.5 % |
Mergers & Acquisitions in Pharmaceuticals
When and how
|
February 2000 |
£165 |
24.15 % |
Rheumatoid Arthritis: Emerging drug discovery targets
And therapeutic candidates
|
October 2003 |
£375 |
24 % |
Allergan, Inc. - SWOT Analysis
|
June 2008 |
£66 |
24 % |
Premium Company Profile: GTx, Inc.
|
November 2007 |
£265 |
24 % |
The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023
|
May 2008 |
£1499 |
24 % |
Antisoma plc
Premium Company Profile
|
April 2008 |
£265 |
24 % |
Cancer Drug Resistance
2008
|
September 2008 |
£1675 |
24 % |
Cancer Stem Cells
Emerging Therapeutic, Diagnostic and Market Opportunities (2008)
|
June 2008 |
£1600 |
24 % |
Market for Bioengineered Protein Drugs; The
|
January 2007 |
£3320 |
23.8 % |
Partneringdesk deals and alliances in gastrointestinal diseases
|
April 2006 |
£1250 |
23.5 % |
Introgen Therapeutics Inc
Premium Company Profile
|
April 2008 |
£265 |
23.5 % |
Partneringdesk deals and alliances in metabolic diseases
|
April 2006 |
£1250 |
23.5 % |
Partneringdesk deals and alliances in genitourinary and gynecological diseases
|
April 2006 |
£1250 |
23.5 % |
Global Clinical Trial Business Report & Analysis 2008-2018
|
July 2008 |
£1499 |
23.45 % |
DNA Sequencing and PCR Markets
|
July 2008 |
£2325 |
23.1 % |
Genomics World Markets
|
May 2008 |
£2325 |
23.1 % |
Gpc Biotech Ag
Premium Company Profile
|
January 2008 |
£265 |
23 % |
Xenoport Inc
Premium Company Profile
|
December 2007 |
£265 |
22.5 % |
Premium Company Profile: OSI Pharmaceuticals
|
November 2007 |
£265 |
22.5 % |
Life Science Tools and Technologies for Bio-Pharma R&D
Instruments, Tech Platforms, Informatics and Market
|
March 2003 |
£1025 |
22.5 % |
GlaxoSmithKline Plc - SWOT Analysis
|
October 2008 |
£66 |
22.5 % |
Pain Therapeutics
Drugs, Markets and Companies
|
December 2008 |
£2055 |
22.5 % |
Sonus Pharmaceuticals Inc: Premium Company Profile
Premium Company Profile
|
January 2008 |
£265 |
22.5 % |
Pharmacovigilance
Risk Management in Practice
|
July 2006 |
£1499 |
22.05 % |
VM Discovery, Inc. -Company Report
|
February 2008 |
£375 |
22 % |
SuperGen, Inc. - SWOT Analysis
|
July 2007 |
£66 |
22 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£3150 |
22 % |
Global Life Sciences Tools & Services
Global Life Sciences Tools & Services
|
March 2007 |
£105 |
22 % |
Premium Company Profile CV Therapeutics
|
October 2007 |
£265 |
22 % |
Pharmaceutical Alliance Management
|
January 2009 |
£5265 |
22 % |
Novo Nordisk A/S - SWOT Analysis
|
June 2008 |
£66 |
21.5 % |
Eli Lilly and Company - SWOT Analysis
|
September 2007 |
£125 |
21.5 % |
Xention Limited (formerly Xention Discovery Ltd) -Company Report
|
February 2008 |
£375 |
21.5 % |
Partneringdesk deals and alliances in musculoskeletal diseases
|
April 2006 |
£1250 |
21 % |
2007 The Worldwide Biochip & Equipment Market
|
August 2006 |
£900 |
21 % |
Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry
|
January 2008 |
£650 |
21 % |
Companion Diagnostics in Personalized Medicine and Cancer Therapy
|
April 2008 |
£2325 |
20.65 % |
Who's Developing What in New Cancer Drugs 2006?
|
November 2007 |
£495 |
20.5 % |
Winning R&D Productivity Strategies
Exploiting innovation, licensing and outsourcing opportunities
|
October 2006 |
£1495 |
20.5 % |
Therapeutic/Diagnostic Devices for Neurological Disorders
|
March 2007 |
£3320 |
20.3 % |
Next Generation Protein Engineering and Drug Design
Strategies to boost efficacy and improve drug delivery
|
February 2007 |
£1495 |
20 % |
Daiichi Sankyo, Ltd. - SWOT Analysis
|
May 2007 |
£66 |
20 % |
Biomarkers
|
January 2008 |
£2270 |
19.95 % |
Roche: Prospects to 2010
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
19.5 % |
Global Functional Genomics Industry
|
November 2002 |
£1840 |
19.5 % |
Gene Expression Reagents Markets
|
April 2007 |
£1370 |
19.25 % |
Live-Licensing & In-life Testing
R&D Processes and Regulation for New Drugs, 2008-2020
|
January 2008 |
£1499 |
19.25 % |
Global Pharmaceuticals, Biotechnology & Life Sciences
Global Pharmaceuticals, Biotechnology & Life Sciences
|
May 2008 |
£230 |
19 % |
Biomarkers: A Market Briefing
A Market Briefing
|
January 2007 |
£1365 |
19 % |
Nanotechnology Opportunity Report, The
|
June 2003 |
£1330 |
18.9 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
18.9 % |
Disposable Syringe Markets
Trends, Industry Participants, Product Overviews and Market Drivers
|
September 2008 |
£1370 |
18.55 % |
Medical Nanotechnology Markets
|
September 2008 |
£2325 |
18.55 % |
Global Antivirals Market Analysis & Forecasts 2008-2023
|
September 2008 |
£1499 |
18.5 % |
Drug Delivery in Central Nervous System Diseases
technologies,markets and companies
|
December 2008 |
£1710 |
18.5 % |
Contract Pharma 2008-2023
|
August 2008 |
£1499 |
18.2 % |
ADME/TOX Technologies
|
January 2008 |
£2000 |
18.2 % |
Drug Repositioning
A market analysis
|
March 2006 |
£1095 |
18 % |
Sgx Pharmaceuticals Inc
Premium Company Profile
|
December 2007 |
£265 |
18 % |
Incremental Improvements And Paradigm Shifts In Strategy Are Both Necessary To Boost Productivity
R&D Strategies
|
August 2007 |
£7600 |
17.85 % |
The World Market for Gynaecology
2007-2017
|
September 2007 |
£3200 |
17.5 % |
Epigenomics
Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
|
March 2007 |
£3320 |
17.5 % |
Innovative And Targeted Cancer Therapies
Key Technologies, New Applications And Leading Players
|
July 2007 |
£1495 |
17.5 % |
Cell Therapy
Technologies, Markets and Companies
|
December 2008 |
£3080 |
17.5 % |
Indian Pharmaceutical Industry
|
July 2008 |
£2325 |
17.15 % |
CNS Drug Discoveries
What the Future Holds
|
November 2006 |
£1995 |
17.15 % |
Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
|
June 2008 |
£2025 |
17 % |
Metabolomics
|
January 2008 |
£1890 |
16.1 % |
Biomarkers: The Future of Next-Generation Drug R&D
|
September 2008 |
£1775 |
16.1 % |
Global Vaccine Market Outlook (2007-2010)
|
June 2007 |
£1095 |
15.5 % |
Premium Company Profile: Invitrogen Corporation
|
November 2007 |
£265 |
15.5 % |
In Vitro Diagnostics Market Report & Analysis 2008-2023
|
June 2008 |
£1499 |
15.4 % |
In-Vitro Diagnostics Market Report & Analysis 2008-2023
|
June 2008 |
£1499 |
15.4 % |
Nanomedicine 2006-2011
|
June 2006 |
£1499 |
15.05 % |
Partneringreview 2006 – Industry Sector
Volume 6
|
February 2006 |
£1395 |
14.5 % |
Antibiotics and Drug Resistance 2008
Drug Innovation and the Strategy to Combat - Antibiotic Resistance Mechanisms
|
January 2008 |
£1499 |
14.35 % |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
14 % |
Partneringreview 2006 – Stage of Development
Volume 4
|
February 2006 |
£1395 |
14 % |
Partneringreview 2006 – Deal Type
Volume 5
|
February 2006 |
£1395 |
13.5 % |
Biologic Imaging Reagents
Technologies and Global Markets
|
December 2008 |
£2150 |
13.5 % |
Partneringreview 2006
|
February 2006 |
£2195 |
13.5 % |
Global Generics Guide
Benchmarking the key players
|
April 2006 |
£4000 |
13.3 % |
Partneringreview 2006 – Financings
Volume 3
|
February 2006 |
£1395 |
13 % |
Partneringreview 2006 – Therapy Area
Volume 2
|
February 2006 |
£1395 |
13 % |
Apoptosis
|
January 2008 |
£1985 |
12.95 % |
Taq Wars; The
Competitive Intelligence on How to Survive
|
November 2005 |
£3080 |
12.6 % |
The Executive Guide to Molecular Imaging
|
July 2007 |
£595 |
12.6 % |
Partneringreview 2006 - Company Deal Index
Volume 1
|
February 2006 |
£1395 |
12.5 % |
High Throughput Screening
|
January 2008 |
£2105 |
12.25 % |
Global Market for Antimicrobials and Antifungals; The
Challenging Resistance to 2016
|
December 2006 |
£1600 |
12.25 % |
Pharmaceutical Regulatory Affairs in the EU and US
|
December 2006 |
£1095 |
12 % |
5th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production
A Study of Biotherapeutic Developers and Contract Manufacturing Organizations, 2007
|
April 2008 |
£1090 |
12 % |
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008
|
May 2007 |
£290 |
10.5 % |
United States in Vitro Diagnostics Industry Report
Detailed Analysis of The Medical Equipment & Medical Devices Market Covering Clinical Chemistry, Immunochemistry, Infectious Immunology, Microbiology, Genetic and Blood Test Reagents, Insturments and Test Kits
|
May 2008 |
£2055 |
10.5 % |
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2008/2009
|
June 2008 |
£290 |
10.5 % |
When Patients Becomes Plaintiffs
A Primer on Drug and Medical Device Liability
|
October 2006 |
£1095 |
7 % |
|
|
|
|
